Studies foam treatment for symptomatic kidney or liver cysts in inherited cyst disease
Observes foam sclerotherapy for large cysts in adults with polycystic kidney or liver disease.
Plain-language title generated from the registry record
Registry title: A Prospective Observational Study of Foam Sclerotherapy .
Key facts
- Where
- Rochester, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT04111692, who can take part
Where in United States
- Mayo ClinicRochester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT04111692
- Record updated
- 26 January 2026
- Original description
An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).Read full original descriptionShow less
A Prospective Observational Study of Foam Sclerotherapy for the Treatment of Symptomatic Kidney or Liver Cysts in Patients With Autosomal Dominant Polycystic Kidney and Liver Disease.
An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).
Inclusion: Age ≥18 years; Clinical diagnosis of ADPKD or ADPLD; 1-3 large, non-exophytic liver or kidney cyst; Compressive symptoms from dominant cyst.
Exclusion: Age <18 years; Absence of ADPKD or ADPLD; Largest cyst <4cm in all 3 dimensions or largest cyst volume <400cc; >3 large, non-exophytic liver or kidney cyst(s) ≥4cm in all 3 dimensions (cyst volume ≥400cc); Unwilling to comply with study follow-up protocol to 12 ± 1months post-FS; Lacking capacity to provide informed consent to FS of liver or kidney cysts; Pregnancy.